Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn

Table of Contents

September 01, 1996; Volume 24,Issue 9
  • You have access
    Dietary indole-3-carbinol inhibits FMO activity and the expression of flavin-containing monooxygenase form 1 in rat liver and intestine.
    S Larsen-Su and D E Williams
    Drug Metabolism and Disposition September 1996, 24 (9) 927-931;
  • You have access
    Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4.
    D E Feierman and J M Lasker
    Drug Metabolism and Disposition September 1996, 24 (9) 932-939;
  • You have access
    Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna-expressed human cytochrome P450.
    A Ghosal, H Satoh, P E Thomas, E Bush and D Moore
    Drug Metabolism and Disposition September 1996, 24 (9) 940-947;
  • You have access
    Catalytic role of cytochrome P4502B6 in the N-demethylation of S-mephenytoin.
    H Heyn, R B White and J C Stevens
    Drug Metabolism and Disposition September 1996, 24 (9) 948-954;
  • You have access
    Ropivacaine, a new amide-type local anesthetic agent, is metabolized by cytochromes P450 1A and 3A in human liver microsomes.
    G Ekström and U B Gunnarsson
    Drug Metabolism and Disposition September 1996, 24 (9) 955-961;
  • You have access
    Metabolism and excretion of ropivacaine in humans.
    M M Halldin, E Bredberg, B Angelin, T Arvidsson, Y Askemark, S Elofsson and M Widman
    Drug Metabolism and Disposition September 1996, 24 (9) 962-968;
  • You have access
    Comparative metabolism of the nonsteroidal antiinflammatory drug, aceclofenac, in the rat, monkey, and human.
    R Bort, X Ponsoda, E Carrasco, M J Gómez-Lechón and J V Castell
    Drug Metabolism and Disposition September 1996, 24 (9) 969-975;
  • You have access
    Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
    D K Spracklin, K E Thummel and E D Kharasch
    Drug Metabolism and Disposition September 1996, 24 (9) 976-983;
  • You have access
    Disposition of gemfibrozil and gemfibrozil acyl glucuronide in the rat isolated perfused liver.
    B C Sallustio, B A Fairchild, K Shanahan, A M Evans and R L Nation
    Drug Metabolism and Disposition September 1996, 24 (9) 984-989;
  • You have access
    Xenobiotic metabolism in rat, dog, and human precision-cut liver slices, freshly isolated hepatocytes, and vitrified precision-cut liver slices.
    S Ekins, J A Williams, G I Murray, M D Burke, N C Marchant, J Engeset and G M Hawksworth
    Drug Metabolism and Disposition September 1996, 24 (9) 990-995;
  • You have access
    Kinetics and selectivity of mechanism-based inhibition of guinea pig hepatic and pulmonary cytochrome P450 by N-benzyl-1-aminobenzotriazole and N-alpha-methylbenzyl-1-aminobenzotriazole.
    C J Sinal and J R Bend
    Drug Metabolism and Disposition September 1996, 24 (9) 996-1001;
  • You have access
    Stereoselective metabolism of a new anticonvulsant drug candidate, losigamone, by human liver microsomes.
    C D Torchin, P J McNeilly, I M Kapetanovic, J M Strong and H J Kupferberg
    Drug Metabolism and Disposition September 1996, 24 (9) 1002-1008;
  • You have access
    Absorption and disposition kinetics of 3,3',4,4'-tetrachloroazoxybenzene in the male Fischer 344 rat.
    T L Ziegler, U A Pillai, R L Smith, M J Kattnig, D C Liebler, M Mayersohn and I G Sipes
    Drug Metabolism and Disposition September 1996, 24 (9) 1009-1014;
  • You have access
    Busulfan conjugation by glutathione S-transferases alpha, mu, and pi.
    M Czerwinski, J P Gibbs and J T Slattery
    Drug Metabolism and Disposition September 1996, 24 (9) 1015-1019;
  • You have access
    Covalent binding to DNA in vitro of 2',3'-oxides derived from allylbenzene analogs.
    G Luo and T M Guenthner
    Drug Metabolism and Disposition September 1996, 24 (9) 1020-1027;
  • You have access
    Hemodynamic effects of N-acetylamrinone in a porcine model of group B streptococcal sepsis.
    E M Allen, M Rowin, J B Pappas, D D Vernon and J M Dean
    Drug Metabolism and Disposition September 1996, 24 (9) 1028-1031;
  • You have access
    Disposition of metabolically radiolabeled CE9.1--a macaque-human chimeric anti-human CD4 monoclonal antibody--in transgenic mice bearing human CD4.
    C B Davis, E M Garver, D C Kwok and J J Urbanski
    Drug Metabolism and Disposition September 1996, 24 (9) 1032-1037;
  • You have access
    Substrate probe for the mechanism of aromatic hydroxylation catalyzed by cytochrome P450.
    J F Darbyshire, K R Iyer, J Grogan, K R Korzekwa and W F Trager
    Drug Metabolism and Disposition September 1996, 24 (9) 1038-1045;
Back to top
PreviousNext

In this issue

Drug Metabolism and Disposition
Vol. 24, Issue 9
1 Sep 1996
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • Cytochrome P450 inhibitors. Evaluation of specificities in the in vitrometabolism of therapeutic agents by human liver microsomes.
  • Prediction of Human Clearance of Twenty-Nine Drugs from Hepatic Microsomal Intrinsic Clearance Data: An Examination of In Vitro Half-Life Approach and Nonspecific Binding to Microsomes
  • DRUG-DRUG INTERACTIONS FOR UDP-GLUCURONOSYLTRANSFERASE SUBSTRATES: A PHARMACOKINETIC EXPLANATION FOR TYPICALLY OBSERVED LOW EXPOSURE (AUCI/AUC) RATIOS
  • In Vitro-In Vivo Scaling of CYP Kinetic Data Not Consistent with the Classical Michaelis-Menten Model
  • THE HUMAN INTESTINAL CYTOCHROME P450 “PIE”
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics